• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Policy

Trump proposes deep cuts to Medicaid, NIH funding

May 23, 2017 By Sarah Faulkner

Capitol Hill

President Donald Trump’s proposed budget would slash Medicaid funding and cut support for major biomedical research programs at the National Institutes of Health and the Centers for Disease Control & Prevention. The budget blueprint drew condemnation from healthcare advocates and lawmakers from both sides of the aisle. Senate majority whip Sen. John Cornyn (R-Texas) reportedly said earlier […]

Filed Under: Featured, Food & Drug Administration (FDA), Funding Roundup, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Capitol Hill, Centers for Medicare and Medicaid Services (CMS), National Institutes of Health

Trump considers drug-pricing reform with input from industry groups, advocates

May 16, 2017 By Sarah Faulkner

Prescription drugs

President Donald Trump’s administration took aim at drug-pricing reform this month by holding listening sessions with industry groups and advocates. His administration is pursuing actions it can take with and without Congress to combat the industry’s high drug prices, according to a report from The Hill. The pharmaceutical industry, traditionally a powerful lobbying force on Capitol […]

Filed Under: Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Capitol Hill

Amid drug-pricing criticism, industry trade group ousts members

May 12, 2017 By Sarah Faulkner

Prescription drugs

The pharmaceutical industry’s trade group ousted 22 companies earlier this week after it revised membership rules. The move comes as lawmakers in Washington have pressed the pharma industry about U.S. drug prices. The updated membership rules for the Pharmaceutical Research and Manufacturers of America (PhRMA) group mandates that members spend at least $200 million each year […]

Filed Under: Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Aerie Pharmaceuticals, amagpharmaceuticals, GlaxoSmithKline plc, jazzpharmaceuticals, johnsonandjohnson, Mallinckrodt Pharmaceuticals, Marathon Pharmaceuticals, Pfizer Inc., The Medicines Co.

Sanofi ties drug price increases to healthcare inflation

May 9, 2017 By Sarah Faulkner

Sanofi logo

Insulin makers have faced questioning this year for their drug pricing practices – a class-action lawsuit filed in the U.S. District Court of Massachusetts in January alleges that Sanofi (NYSE:SNY), Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) conspired to raise their list prices to get access to pharmacy benefit managers’ preferred lists, instead of competing with each other […]

Filed Under: Diabetes, Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Eli Lilly & Co., Novo Nordisk, Sanofi-Aventis

Report: Pharma relies on price hikes for growth

April 25, 2017 By Sarah Faulkner

Prescription drugs

Despite growing pressure from lawmakers over the pharmaceutical industry’s pricey products, new research shows that pharma relied largely on price hikes for growth in 2016. A 120-page report from Credit Suisse demonstrated that net price growth made up 100% of net income growth for a variety of companies within the industry, including Biogen (NSDQ:BIIB), Eli Lilly […]

Filed Under: Featured, Pharmaceuticals, Policy Tagged With: Allergan, Biogen Idec, Eli Lilly & Co., Novo Nordisk, Regeneron

Trump to meet with biotech execs, researchers to discuss federal funding

April 24, 2017 By Sarah Faulkner

capitol hill

In the wake of President Donald Trump’s $6 billion proposed cut to the National Institutes of Health, biotech executives and researchers are slated to meet with the new administration next month. A memo about the meeting reportedly describes the get-together as a chance for the “private sector and thought leaders to describe their institution and […]

Filed Under: Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: National Institutes of Health

UPDATED: Mallinckrodt, Marathon leave industry trade group over drug pricing controversy

April 21, 2017 By Sarah Faulkner

Prescription drugs

Updated to include a statement from Mallinckrodt regarding its membership with PhRMA.  Marathon Pharmaceuticals reportedly withdrew from the drug industry’s lobbying group yesterday following controversy over its pricey drug, Emflaza. Pharmaceutical Research and Manufacturers of America (PhRMA) began reconsidering its membership criteria as reports revealed a number of drugmakers hiking the prices of their products. […]

Filed Under: Featured, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Mallinckrodt Pharmaceuticals, Marathon Pharmaceuticals, PTC therapeutics

Medicaid expansion tied to increase in prescriptions for diabetes drugs, birth control

April 20, 2017 By Sarah Faulkner

Prescription drugs

The number of prescriptions filled by adults using Medicaid rose 19% in states that expanded Medicaid compared to states that did not under the Affordable Care Act, according to a new study from the Harvard T.H. Chan School of Public Health. The largest increases were for drugs that help patients deal with chronic conditions, including […]

Filed Under: Diabetes, Featured, Pharmaceuticals, Policy Tagged With: Capitol Hill, Harvard University

Trump FDA pick to recuse himself from agency decisions involving 20 companies

March 29, 2017 By Sarah Faulkner

FDA

Donald Trump’s nominee to head the FDA, Dr. Scott Gottlieb, reportedly told ethics officials at the Office of Government Ethics he plans to recuse himself for 1 year from agency decisions on more than 20 companies, including GlaxoSmithKline (NYSE:GSK) and Bristol-Myers Squibb (NYSE:BMY). Gottlieb has received millions of dollars for his roles as advisor, paid speaker […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Policy, Regulatory/Compliance, Wall Street Beat Tagged With: Biogen Idec, Bristol-Myers Squibb Co., GlaxoSmithKline plc, Merck

Little or no audit preparation common device QMS problem

March 24, 2017 By Danielle Kirsh

By Stewart Eisenhart, Emergo Group In the second in a series of blog posts examining common problems medical device firms deal with related to quality management system audits, Emergo discusses how lack of proper internal audit preparation leads to last-minute scrambles and business headaches. Get the full story here at the Emergo Group’s blog. The […]

Filed Under: Policy Tagged With: blog, Emergo Group

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Interim pages omitted …
  • Page 8
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS